• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名免疫抑制女性因皮肤带状疱疹导致的慢性腿部溃疡和皮下脂膜炎

Chronic Leg Ulcerations and Subcutaneous Panniculitis due to Dermal Herpes Zoster in an Immunosuppressed Woman.

作者信息

Al-Dojaily Yasir, Omesiete Wilson, Flowers R Hal, Gradecki Sarah E, Lim Olivia V

机构信息

Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Department of Dermatology, University of Virginia Health System, Charlottesville, Virginia, USA.

出版信息

J Cutan Pathol. 2025 Feb;52(2):113-117. doi: 10.1111/cup.14767. Epub 2024 Dec 3.

DOI:10.1111/cup.14767
PMID:39625038
Abstract

Herpes zoster (HZ) is a cutaneous viral disease that typically presents with a dermatomal vesicular eruption. Immunosuppressed patients are more likely to have atypical HZ involving chronic ulceration and disseminated distribution, making diagnosis a challenge. The current report describes a unique case of HZ in a woman with systemic lupus on immunosuppressive therapy manifesting as persistent lower extremity ulceration with diffuse dermal and endothelial infection and secondary panniculitis without epidermal involvement. Other potential etiologies were thoroughly excluded. The ulceration successfully responded to several weeks of valacyclovir. Recognizing atypical clinicopathologic manifestations of HZ in the setting of immune compromise is critical to accurate diagnosis and prompt therapy.

摘要

带状疱疹(HZ)是一种皮肤病毒性疾病,通常表现为沿皮节的水疱性皮疹。免疫抑制患者更易发生非典型HZ,表现为慢性溃疡和播散性分布,这使得诊断颇具挑战性。本报告描述了一例独特的HZ病例,患者为一名接受免疫抑制治疗的系统性红斑狼疮女性,表现为下肢持续性溃疡,伴有弥漫性真皮和内皮感染及继发性脂膜炎,无表皮受累。其他潜在病因均被彻底排除。溃疡经数周的伐昔洛韦治疗后成功愈合。认识到免疫功能低下情况下HZ的非典型临床病理表现对于准确诊断和及时治疗至关重要。

相似文献

1
Chronic Leg Ulcerations and Subcutaneous Panniculitis due to Dermal Herpes Zoster in an Immunosuppressed Woman.一名免疫抑制女性因皮肤带状疱疹导致的慢性腿部溃疡和皮下脂膜炎
J Cutan Pathol. 2025 Feb;52(2):113-117. doi: 10.1111/cup.14767. Epub 2024 Dec 3.
2
Non-dermatomal varicella-zoster skin infection: disseminated cutaneous herpes zoster without dermatome in an immunosuppressed woman.非皮节性水痘-带状疱疹皮肤感染:一名免疫抑制女性发生的无皮节分布的播散性皮肤带状疱疹。
Dermatol Online J. 2017 Oct 15;23(10):13030/qt36j330n5.
3
Herpes zoster: diagnostic, therapeutic, and preventive approaches.带状疱疹:诊断、治疗和预防方法。
Postgrad Med. 2013 Sep;125(5):78-91. doi: 10.3810/pgm.2013.09.2703.
4
Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.水痘带状疱疹性脑膜炎并发克罗恩病的肿瘤坏死因子和皮质类固醇联合治疗。
World J Gastroenterol. 2013 Jun 7;19(21):3347-51. doi: 10.3748/wjg.v19.i21.3347.
5
Zoster cruralgia in a pregnant woman.一名孕妇的股部带状疱疹后神经痛
Joint Bone Spine. 2009 Dec;76(6):724-5. doi: 10.1016/j.jbspin.2009.04.008.
6
Varicella-zoster meningitis with a late-onset of skin eruption.水痘-带状疱疹性脑膜炎伴皮疹延迟出现。
BMJ Case Rep. 2015 Feb 17;2015:bcr2014208056. doi: 10.1136/bcr-2014-208056.
7
Failure of valacyclovir for herpes zoster in a moderately immunocompromised HIV-infected patient.伐昔洛韦对一名中度免疫功能低下的HIV感染患者的带状疱疹治疗失败。
AIDS Patient Care STDS. 2004 May;18(5):255-7. doi: 10.1089/108729104323075990.
8
Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients.伐昔洛韦与阿昔洛韦治疗免疫功能正常患者的眼部带状疱疹
Cochrane Database Syst Rev. 2016 Nov 14;11(11):CD011503. doi: 10.1002/14651858.CD011503.pub2.
9
Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.一项关于伐昔洛韦每日两次、每次1.5克用于治疗18岁及以上免疫功能正常患者的非复杂性带状疱疹的开放标签研究。
J Cutan Med Surg. 2007 May-Jun;11(3):89-98. doi: 10.2310/7750.2007.00016.
10
Valacyclovir in the treatment of genital herpes and herpes zoster.伐昔洛韦治疗生殖器疱疹和带状疱疹。
Expert Opin Pharmacother. 2002 Jan;3(1):51-8. doi: 10.1517/14656566.3.1.51.